Developer docs
API playgroundTry for free, no card

Search company profiles

SOCIUM

Full company profile

uuid00045xr

Namestring
SOCIUM
Legal namestring
SOCIUM Inc.
Websiteurl
socium.co.jp
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SOCIUM Inc. is a Tokyo-based, privately-held AI drug-discovery venture founded in September 2017 by CEO Katsuhisa Horimoto, Ph.D., that develops first-in-class small molecules through drug repositioning focused on rare and intractable diseases, alongside a proprietary phosphorylation-analysis service business. The technical core comprises three in-house AI platforms — Compound-Eyes™ (target identification from gene-expression patterns), Drug Saver™ (repositioning of existing drugs into new indications), and Cyber-Drug-Discovery™ (mechanism-of-action elucidation) — combined with Phospho-Totum, a patented platform (Patent No. 6884389) that simultaneously measures phosphorylation of 1,471 protein substrates on glass arrays and infers activation of 273 signaling pathways and 185 kinases. This coupling of computational prediction with wet-lab pathway readouts underpins the company's Umbrella Drug Discovery strategy, which seeks a single compound effective across multiple diseases sharing common molecular mechanisms.

SOCIUM's commercial activity operates through three workstreams: (1) phosphorylation analysis services sold to pharmaceutical companies, research institutions, and universities globally (Japan, China, distributed in the U.S. by Canon Virginia), (2) AI-platform licensing and co-development partnerships with Japanese pharma (e.g., Sumitomo Dainippon Pharma on tauopathy neuroprotection, RaQualia Pharma on orphan indications) and Chinese partners (LTT Bio-Pharma, Suzhou Brainlight Biomedical Technology), and (3) internal drug-candidate development. The clinical-stage pipeline is led by SO-002 (cycloserine, repositioned for ALS; Patent No. 7660827) — granted PMDA Phase I exemption and Phase II approval in January 2023, with an investigator-initiated trial at Sichuan University Huaxi Hospital that completed enrollment of 20 ALS patients in June 2026 — and SO-003, a TDP43 aggregation inhibitor for muscle cells in TDP43 protein-opathy, in an investigator-initiated trial at Nanjing Medical University Sir Run Run Hospital (kickoff December 2025), with a joint patent application accepted in May 2025.

Revenue mechanics are early-stage and not publicly disclosed. The company has been capitalized primarily through Series A and Series B rounds totaling approximately ¥510M (~$4.6M) led by University of Tokyo Edge Capital, additional Series B participation from the National Institute of Advanced Industrial Science and Technology (AIST), a ~$1M NEDO grant in 2018, and equity crowdfunding via FUNDINNO in 2024-2025. Headcount is in the 11-50 range; headquarters are in Nihonbashi-Kabuto-cho, Chuo-ku, Tokyo, with research operations now at Shonan Health Innovation Park (Shonan iPark), Fujisawa, Kanagawa (relocated September 2025) and a growing clinical and commercial footprint across China and the United States.

Short descriptiontext

SOCIUM is a Tokyo-based AI drug-discovery venture founded in 2017 that uses proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) and a patented phosphorylation-analysis system (Phospho-Totum) to reposition existing drugs and develop first-in-class small molecules, primarily for rare diseases, serving pharmaceutical companies, research institutions, and hospitals through B2B partnerships and clinical collaborations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, drug repositioning, phosphorylation analysis, rare disease therapeutics, small molecule development
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Phosphorylation Analysis Services
TypeProfessional Services
Description

Provides phosphorylation pathway analysis services to pharmaceutical companies, research institutions, and universities globally. Measures phosphorylation levels and estimates kinase activity for drug discovery and validation purposes.

socium.co.jp
2Drug Discovery Licensing and Partnerships
TypeLicensing Royalties
Description

Licenses proprietary AI drug repositioning platforms to pharmaceutical partners. Revenue from strategic alliances for co-development of drug candidates, particularly in rare diseases.

socium.co.jp
3Drug Development
TypeLicensing Royalties
Description

Developing proprietary drug candidates (SO-002, SO-003) for rare diseases. Revenue potential through licensing out drug candidates post-clinical validation.

socium.co.jp
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Compound-Eyes™
Description

Proprietary AI drug discovery platform for identifying novel drug targets

socium.co.jp
+3 more records
Core offering1 text field

SOCIUM is an AI-driven drug discovery and development company that uses proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) to identify new indications for existing drugs through drug repositioning, with a focus on rare diseases such as ALS and TDP43 protein-opathy. The company also offers Phospho-Totum, a comprehensive phosphorylation analysis service that measures phosphorylation states of 1,471 proteins on glass plates to estimate kinase activity and pathway activation for drug mechanism validation. Its pipeline includes two therapeutic candidates (SO-002 for ALS and SO-003 for TDP43 protein-opathy) currently in investigator-initiated clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Target enrollment of 20 ALS patients achieved in approximately 6 months for SO-002 clinical trial
+2 more records
Product overview1 text field

SOCIUM is a drug discovery venture company offering two main segments: (1) Discovery and Development of Drugs using proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) for drug repositioning to find new indications for existing drugs, and (2) Phosphorylation Analysis Services through Phospho-Totum, the world's first system that comprehensively measures phosphorylation states in cells. The company's Umbrella Drug Discovery strategy explores single drugs for multiple diseases with common molecular mechanisms. Current pipeline includes SO-002 (ALS treatment candidate in clinical trials) and SO-003 (TDP43 protein-opathy treatment candidate in clinical trials).

Product and service4 records
1Phospho-Totum Phosphorylation Analysis Service
CategoryPhosphorylation Analysis Service
Description

World's first comprehensive phosphorylation analysis service that measures phosphorylation states of 1,471 protein substrates on glass plates and estimates kinase activity and pathway activation. Provided to pharmaceutical companies, research institutions, and universities globally for drug mechanism validation and kinase activity profiling.

2AI-Driven Drug Discovery and Repositioning Service
CategoryDrug Discovery Service
Description

Drug discovery and repositioning service using proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) to identify new indications for existing drugs and discover first-in-class small molecule candidates, with focus on rare diseases and unmet medical needs. Delivered via strategic alliances, co-development agreements, and licensing partnerships with pharmaceutical companies.

3SO-002 (ALS Therapeutic Candidate)
CategoryTherapeutic Drug Candidate
Description

Therapeutic drug candidate (cycloserine) for ALS treatment that restores ALS patient gene expression patterns to healthy levels. Discovered through SOCIUM's proprietary computational AI analysis. Currently in Phase II investigator-initiated clinical trial at Sichuan University Huaxi Hospital in China. Patent-protected (Patent No. 7660827) and PMDA-approved.

4SO-003 (TDP43 Protein-opathy Therapeutic Candidate)
CategoryTherapeutic Drug Candidate
Description

Therapeutic drug candidate targeting muscle cells for TDP43 protein-opathy. Reduces TDP-43 aggregation in muscle cells and is expected to improve lower motor neuron function. Joint patent filed with Nanjing Medical University. Investigator-initiated clinical trial underway at Nanjing Medical University Sir Run Run Hospital.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Nanjing Medical University Sir Run Run Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Second investigator-initiated clinical trial for TDP43 aggregation inhibitor (SO-003) targeting muscle cells in TDP43 protein-opathy. Kickoff meeting held November 2025.

socium.co.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-31
Description

Strategic joint research agreement to combine SOCIUM's AI drug repositioning platform with LTT Bio-Pharma's proprietary disease model evaluation system. Aims to create a drug repositioning ecosystem combining biology and AI, and accelerate Japan-China drug discovery collaborations.

3Suzhou Brainlight Biomedical Technology Co., Ltd (苏州铂莱特医药科技有限公司)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-22
Description

Cooperation agreement covering phosphorylation array analysis services, therapeutic drug seeds discovery and development, and investigator-initiated clinical trials. Combines SOCIUM's drug repositioning technology with Suzhou Brainlight's compound synthesis and efficacy verification technology.

socium.co.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Conducting investigator-initiated clinical trial for ALS treatment candidate SO-002 at one of China's largest hospitals (4,900 beds, ranked 2nd nationally). Trial approved by ethics committee in September 2024.

5Nanjing Medical University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing Japan-China collaboration for drug development. Includes joint research, joint patent filings, and clinical trial coordination. Part of JICA-supported Japan-China Cooperation Project.

socium.co.jp
6Canon Virginia, Inc.
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

US partner promoting phosphorylation analysis services and supporting exhibition at conferences including AACR Annual Meeting 2026.

socium.co.jp
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research collaboration on phosphorylation analysis for acute myeloid leukemia drug mechanism elucidation. Published in Signal Transduction and Targeted Therapy (IF 40.8).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Meetings held during US promotion tour to explore collaboration on phosphorylation services.

9National Institute of Advanced Industrial Science and Technology (AIST)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SOCIUM originated from AIST. Ongoing joint research and technology development. AIST provided Series B investment through third-party allocation.

socium.co.jp
10Sumitomo Dainippon Pharma Co., Ltd.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research agreement for revealing neuroprotective mechanism in tauopathy using SOCIUM's drug discovery platforms.

socium.co.jp
11RaQualia Pharma Inc.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research agreement for discovering orphan indications for RaQualia Pharma's specific compound using SOCIUM's AI platforms.

socium.co.jp
12Keio University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research agreement for AI-driven drug discovery for aging-related diseases.

socium.co.jp
13Tokushima University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research agreement for AI-driven drug discovery for rare gastrointestinal tumors.

socium.co.jp
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven drug repurposing company specifically focused on rare diseases. Most comparable to SOCIUM's rare disease repositioning strategy, though typically working with existing approved drugs rather than proprietary small molecule discovery.

TypeEmerging player
Description

Specialty proteomics services company focused on kinome analysis, signaling pathway profiling, and phosphorylation-related services. Comparable to SOCIUM's Phospho-Totum phosphorylation analysis service for kinase activity profiling and drug mechanism studies.

TypeDirect peer
Description

AI-native pharma company using AI for small molecule design and drug discovery partnerships with major pharma. Direct competitor in AI-driven small molecule discovery, with established pharma partnerships and clinical assets overlapping SOCIUM's repositioning and first-in-class focus.

TypeDirect peer
Description

AI-driven drug discovery company with end-to-end platform spanning target identification, generative chemistry, and clinical development. Comparable to SOCIUM's AI repositioning approach, with a similarly broad Asia-Western footprint but deeper capital and multiple clinical-stage assets.

TypeEmerging player
Description

AI-augmented drug discovery platform focused on polypharmacology, deep profiling of compounds, and drug repositioning. Comparable to SOCIUM's multi-target/disease approach, though smaller scale and focused more on platform partnerships than internal pipeline.

TypeDirect peer
Description

AI- and physics-based drug discovery company combining computational chemistry with automation for small molecule design and crystal structure prediction. Closely comparable Asian-headquartered AI drug discovery peer with similar platform approach and pharma partnerships.

TypeDirect peer
Description

AI drug discovery company using knowledge graphs and ML to identify new drug targets and indications. Directly comparable to SOCIUM's drug repositioning focus on identifying new indications for existing compounds, especially for rare and underserved diseases.

TypeDirect peer
Description

Clinical-stage AI drug discovery company combining high-throughput biology with proprietary ML to identify novel therapeutics across multiple indications. Direct competitor to SOCIUM's Compound-Eyes™ and Drug Saver™ platforms, with a much larger pipeline and capital base.

TypeBroad incumbent
Description

Major provider of antibodies, kits, and services for cell signaling research, including phosphorylation analysis. Closest direct comparator for SOCIUM's Phospho-Totum phosphorylation analysis service, operating at much larger scale across global pharma and academic customers.

TypeDirect peer
Description

Physics-based computational platform company providing software and services for drug discovery, including target identification and molecular design. Comparable to SOCIUM's computational/AI platforms but with a software-centric business model and broader pharma customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SOCIUM

Drug Discovery Servicessocium.co.jp

SOCIUM is a Tokyo-based AI drug-discovery venture founded in 2017 that uses proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) and a patented phosphorylation-analysis system (Phospho-Totum) to reposition existing drugs and develop first-in-class small molecules, primarily for rare diseases, serving pharmaceutical companies, research institutions, and hospitals through B2B partnerships and clinical collaborations.

What SOCIUM does

SOCIUM Inc. is a Tokyo-based, privately-held AI drug-discovery venture founded in September 2017 by CEO Katsuhisa Horimoto, Ph.D., that develops first-in-class small molecules through drug repositioning focused on rare and intractable diseases, alongside a proprietary phosphorylation-analysis service business. The technical core comprises three in-house AI platforms — Compound-Eyes™ (target identification from gene-expression patterns), Drug Saver™ (repositioning of existing drugs into new indications), and Cyber-Drug-Discovery™ (mechanism-of-action elucidation) — combined with Phospho-Totum, a patented platform (Patent No. 6884389) that simultaneously measures phosphorylation of 1,471 protein substrates on glass arrays and infers activation of 273 signaling pathways and 185 kinases. This coupling of computational prediction with wet-lab pathway readouts underpins the company's Umbrella Drug Discovery strategy, which seeks a single compound effective across multiple diseases sharing common molecular mechanisms.

SOCIUM's commercial activity operates through three workstreams: (1) phosphorylation analysis services sold to pharmaceutical companies, research institutions, and universities globally (Japan, China, distributed in the U.S. by Canon Virginia), (2) AI-platform licensing and co-development partnerships with Japanese pharma (e.g., Sumitomo Dainippon Pharma on tauopathy neuroprotection, RaQualia Pharma on orphan indications) and Chinese partners (LTT Bio-Pharma, Suzhou Brainlight Biomedical Technology), and (3) internal drug-candidate development. The clinical-stage pipeline is led by SO-002 (cycloserine, repositioned for ALS; Patent No. 7660827) — granted PMDA Phase I exemption and Phase II approval in January 2023, with an investigator-initiated trial at Sichuan University Huaxi Hospital that completed enrollment of 20 ALS patients in June 2026 — and SO-003, a TDP43 aggregation inhibitor for muscle cells in TDP43 protein-opathy, in an investigator-initiated trial at Nanjing Medical University Sir Run Run Hospital (kickoff December 2025), with a joint patent application accepted in May 2025.

Revenue mechanics are early-stage and not publicly disclosed. The company has been capitalized primarily through Series A and Series B rounds totaling approximately ¥510M (~$4.6M) led by University of Tokyo Edge Capital, additional Series B participation from the National Institute of Advanced Industrial Science and Technology (AIST), a ~$1M NEDO grant in 2018, and equity crowdfunding via FUNDINNO in 2024-2025. Headcount is in the 11-50 range; headquarters are in Nihonbashi-Kabuto-cho, Chuo-ku, Tokyo, with research operations now at Shonan Health Innovation Park (Shonan iPark), Fujisawa, Kanagawa (relocated September 2025) and a growing clinical and commercial footprint across China and the United States.

SOCIUM firmographics

Firmographics
Name
SOCIUM
Legal name
SOCIUM Inc.
Website
https://socium.co.jp
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
SOCIUM is a Tokyo-based AI drug-discovery venture founded in 2017 that uses proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) and a patented phosphorylation-analysis system (Phospho-Totum) to reposition existing drugs and develop first-in-class small molecules, primarily for rare diseases, serving pharmaceutical companies, research institutions, and hospitals through B2B partnerships and clinical collaborations.
Ownership category
akta.pro rank

SOCIUM industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • AI drug discovery
  • Drug repositioning
  • Phosphorylation analysis
  • Rare disease therapeutics
  • Small molecule development

Where SOCIUM is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

SOCIUM business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Phosphorylation Analysis Services: Provides phosphorylation pathway analysis services to pharmaceutical companies, research institutions, and universities globally. Measures phosphorylation levels and estimates kinase activity for drug discovery and validation purposes.
  2. Drug Discovery Licensing and Partnerships: Licenses proprietary AI drug repositioning platforms to pharmaceutical partners. Revenue from strategic alliances for co-development of drug candidates, particularly in rare diseases.
  3. Drug Development: Developing proprietary drug candidates (SO-002, SO-003) for rare diseases. Revenue potential through licensing out drug candidates post-clinical validation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

SOCIUM product offering

Product offering

Core offering

SOCIUM is an AI-driven drug discovery and development company that uses proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) to identify new indications for existing drugs through drug repositioning, with a focus on rare diseases such as ALS and TDP43 protein-opathy. The company also offers Phospho-Totum, a comprehensive phosphorylation analysis service that measures phosphorylation states of 1,471 proteins on glass plates to estimate kinase activity and pathway activation for drug mechanism validation. Its pipeline includes two therapeutic candidates (SO-002 for ALS and SO-003 for TDP43 protein-opathy) currently in investigator-initiated clinical trials.

Product overview

SOCIUM is a drug discovery venture company offering two main segments: (1) Discovery and Development of Drugs using proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) for drug repositioning to find new indications for existing drugs, and (2) Phosphorylation Analysis Services through Phospho-Totum, the world's first system that comprehensively measures phosphorylation states in cells. The company's Umbrella Drug Discovery strategy explores single drugs for multiple diseases with common molecular mechanisms. Current pipeline includes SO-002 (ALS treatment candidate in clinical trials) and SO-003 (TDP43 protein-opathy treatment candidate in clinical trials).

Differentiator

Problem solved

Functional benefit

Brands

  • Compound-Eyes™: Proprietary AI drug discovery platform for identifying novel drug targets
  • Drug Saver™
  • Cyber-Drug-Discovery™
  • Phospho-Totum (Patent No. 6884389)

Products and services

  • Phospho-Totum Phosphorylation Analysis Service World's first comprehensive phosphorylation analysis service that measures phosphorylation states of 1,471 protein substrates on glass plates and estimates kinase activity and pathway activation. Provided to pharmaceutical companies, research institutions, and universities globally for drug mechanism validation and kinase activity profiling.
  • AI-Driven Drug Discovery and Repositioning Service Drug discovery and repositioning service using proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) to identify new indications for existing drugs and discover first-in-class small molecule candidates, with focus on rare diseases and unmet medical needs. Delivered via strategic alliances, co-development agreements, and licensing partnerships with pharmaceutical companies.
  • SO-002 (ALS Therapeutic Candidate) Therapeutic drug candidate (cycloserine) for ALS treatment that restores ALS patient gene expression patterns to healthy levels. Discovered through SOCIUM's proprietary computational AI analysis. Currently in Phase II investigator-initiated clinical trial at Sichuan University Huaxi Hospital in China. Patent-protected (Patent No. 7660827) and PMDA-approved.
  • SO-003 (TDP43 Protein-opathy Therapeutic Candidate) Therapeutic drug candidate targeting muscle cells for TDP43 protein-opathy. Reduces TDP-43 aggregation in muscle cells and is expected to improve lower motor neuron function. Joint patent filed with Nanjing Medical University. Investigator-initiated clinical trial underway at Nanjing Medical University Sir Run Run Hospital.

Quantifiable outcome

  • Target enrollment of 20 ALS patients achieved in approximately 6 months for SO-002 clinical trial
  • +2 more outcomes

Companies that use SOCIUM

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

SOCIUM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

SOCIUM partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Nanjing Medical University Sir Run Run HospitalcoreStrategic or Co-development Partner · 1 December 2025Second investigator-initiated clinical trial for TDP43 aggregation inhibitor (SO-003) targeting muscle cells in TDP43 protein-opathy. Kickoff meeting held November 2025.
  • LTT Bio-Pharma Co.LtdcoreStrategic or Co-development Partner · 31 July 2025Strategic joint research agreement to combine SOCIUM's AI drug repositioning platform with LTT Bio-Pharma's proprietary disease model evaluation system. Aims to create a drug repositioning ecosystem combining biology and AI, and accelerate Japan-China drug discovery collaborations.
  • Suzhou Brainlight Biomedical Technology Co., Ltd (苏州铂莱特医药科技有限公司)coreStrategic or Co-development Partner · 22 July 2025Cooperation agreement covering phosphorylation array analysis services, therapeutic drug seeds discovery and development, and investigator-initiated clinical trials. Combines SOCIUM's drug repositioning technology with Suzhou Brainlight's compound synthesis and efficacy verification technology.
  • Sichuan University Huaxi HospitalcoreStrategic or Co-development Partner · 17 September 2024Conducting investigator-initiated clinical trial for ALS treatment candidate SO-002 at one of China's largest hospitals (4,900 beds, ranked 2nd nationally). Trial approved by ethics committee in September 2024.
  • Nanjing Medical UniversitycoreStrategic or Co-development PartnerLong-standing Japan-China collaboration for drug development. Includes joint research, joint patent filings, and clinical trial coordination. Part of JICA-supported Japan-China Cooperation Project.
  • Canon Virginia, Inc.minorChannel Partner/ Reseller/ DistributorUS partner promoting phosphorylation analysis services and supporting exhibition at conferences including AACR Annual Meeting 2026.
  • Virginia Commonwealth UniversityminorStrategic or Co-development PartnerJoint research collaboration on phosphorylation analysis for acute myeloid leukemia drug mechanism elucidation. Published in Signal Transduction and Targeted Therapy (IF 40.8).
  • Johns Hopkins UniversityminorStrategic or Co-development PartnerMeetings held during US promotion tour to explore collaboration on phosphorylation services.
  • National Institute of Advanced Industrial Science and Technology (AIST)coreStrategic or Co-development PartnerSOCIUM originated from AIST. Ongoing joint research and technology development. AIST provided Series B investment through third-party allocation.
  • Sumitomo Dainippon Pharma Co., Ltd.minorStrategic or Co-development PartnerJoint research agreement for revealing neuroprotective mechanism in tauopathy using SOCIUM's drug discovery platforms.
  • RaQualia Pharma Inc.minorStrategic or Co-development PartnerJoint research agreement for discovering orphan indications for RaQualia Pharma's specific compound using SOCIUM's AI platforms.
  • Keio UniversityminorStrategic or Co-development PartnerJoint research agreement for AI-driven drug discovery for aging-related diseases.
  • Tokushima UniversityminorStrategic or Co-development PartnerJoint research agreement for AI-driven drug discovery for rare gastrointestinal tumors.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

SOCIUM competitors and assessment

Company assessment

Emerging players

  • Healx: AI-driven drug repurposing company specifically focused on rare diseases. Most comparable to SOCIUM's rare disease repositioning strategy, though typically working with existing approved drugs rather than proprietary small molecule discovery.
  • Kinexus Bioinformatics: Specialty proteomics services company focused on kinome analysis, signaling pathway profiling, and phosphorylation-related services. Comparable to SOCIUM's Phospho-Totum phosphorylation analysis service for kinase activity profiling and drug mechanism studies.
  • Cyclica: AI-augmented drug discovery platform focused on polypharmacology, deep profiling of compounds, and drug repositioning. Comparable to SOCIUM's multi-target/disease approach, though smaller scale and focused more on platform partnerships than internal pipeline.

Direct peers

  • Exscientia: AI-native pharma company using AI for small molecule design and drug discovery partnerships with major pharma. Direct competitor in AI-driven small molecule discovery, with established pharma partnerships and clinical assets overlapping SOCIUM's repositioning and first-in-class focus.
  • Insilico Medicine: AI-driven drug discovery company with end-to-end platform spanning target identification, generative chemistry, and clinical development. Comparable to SOCIUM's AI repositioning approach, with a similarly broad Asia-Western footprint but deeper capital and multiple clinical-stage assets.
  • XtalPi: AI- and physics-based drug discovery company combining computational chemistry with automation for small molecule design and crystal structure prediction. Closely comparable Asian-headquartered AI drug discovery peer with similar platform approach and pharma partnerships.
  • BenevolentAI: AI drug discovery company using knowledge graphs and ML to identify new drug targets and indications. Directly comparable to SOCIUM's drug repositioning focus on identifying new indications for existing compounds, especially for rare and underserved diseases.
  • Recursion Pharmaceuticals: Clinical-stage AI drug discovery company combining high-throughput biology with proprietary ML to identify novel therapeutics across multiple indications. Direct competitor to SOCIUM's Compound-Eyes™ and Drug Saver™ platforms, with a much larger pipeline and capital base.
  • Schrödinger: Physics-based computational platform company providing software and services for drug discovery, including target identification and molecular design. Comparable to SOCIUM's computational/AI platforms but with a software-centric business model and broader pharma customer base.

Broad incumbents

  • Cell Signaling Technology: Major provider of antibodies, kits, and services for cell signaling research, including phosphorylation analysis. Closest direct comparator for SOCIUM's Phospho-Totum phosphorylation analysis service, operating at much larger scale across global pharma and academic customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SOCIUM social profiles

Digital presence

SOCIUM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SOCIUM leadership team

Management profile

Number of profiles

Profiles4 records

SOCIUM funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SOCIUM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOCIUM

What does SOCIUM do?

SOCIUM is an AI-driven drug discovery and development company that uses proprietary AI platforms (Compound-Eyes™, Drug Saver™, Cyber-Drug-Discovery™) to identify new indications for existing drugs through drug repositioning, with a focus on rare diseases such as ALS and TDP43 protein-opathy. The company also offers Phospho-Totum, a comprehensive phosphorylation analysis service that measures phosphorylation states of 1,471 proteins on glass plates to estimate kinase activity and pathway activation for drug mechanism validation. Its pipeline includes two therapeutic candidates (SO-002 for ALS and SO-003 for TDP43 protein-opathy) currently in investigator-initiated clinical trials.

Is SOCIUM a public or private company?

SOCIUM is a private company. It is classified as venture growth investor backed and is currently operating.

When was SOCIUM founded?

SOCIUM was founded in 2017. It employs 1 to 10 people.

Where is SOCIUM based?

SOCIUM is headquartered in Tokyo, Japan, in the Asia region.

How does SOCIUM make money?

Three revenue lines are on record. Phosphorylation Analysis Services are the primary driver. The others are drug Discovery Licensing and Partnerships and drug Development.

Who are SOCIUM's main competitors?

Emerging players on record are Healx, Kinexus Bioinformatics and Cyclica. Direct peers are Exscientia, Insilico Medicine, XtalPi, BenevolentAI, Recursion Pharmaceuticals and Schrödinger. Cell Signaling Technology is listed as a broad incumbent.

Does SOCIUM have an API?

No public API is recorded for SOCIUM.

What industry is SOCIUM in?

SOCIUM's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Socium Advisors: Amplify Wealth Partners Acquisition Expands Retirement And Benefits CapabilitiesSocium Advisors announced the integration of Amplify Wealth Partners into its platform, a strategic move that expands its capabilities across retirement planning, group benefits, and comprehensive wealth management services. The combined entity now oversees more than $4.3 billion in assets under management and has grown to nearly 90 professionals, positioning it among the larger firms within the Northwestern Mutual network. The deal is designed to enhance existing client relationships while providing clients access to expanded resources, specialized expertise, and a broader range of services including estate planning, philanthropic planning, and employee benefits solutions.Wealth ManagementSocium Advisors Adds Amplify Wealth Partners, ExpandsSocium Advisors, a St. Louis-based Northwestern Mutual private client group, announced the acquisition of Milwaukee-based Amplify Wealth Partners, which manages $1.6 billion in client assets. The deal increases Socium's total client assets to $4.3 billion and adds 26 financial professionals across five new partners, making it one of the largest wealth management firms in Northwestern Mutual's network. The acquisition expands Socium's geographic presence to nine offices across the United States and enables expansion into additional states.PrivateequitywireAtwater Capital selects Socium Fund Services for fund administration - Private Equity WireSocium Fund Services will provide fund administration to Atwater Capital, a private investment firm in media and entertainment. Socium offers services including partnership accounting, financial reporting, and capital call processing. Atwater's Managing Partner said the firm chose Socium to focus on investment activities.